Exane Derivatives’s Sanofi SNY Stock Holding History

Exane Derivatives’s Portfolio SNY Stock Details SNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-10	Closed	-$50	–	637
2017 Q2	$50	Buy	+10	New	+$478	﹤0.01%	587
2017 Q1	–	Sell	-53	Closed	-$999	–	669
2016 Q4	$999	Buy	+53	New	+$2.09K	﹤0.01%	475
2016 Q1	–	Sell	-216	Closed	-$64.8K	–	612
2015 Q4	$64.8K	Buy	216 +5	+2%	+$230	0.01%	248
2015 Q3	$49.5K	Buy	+211	New	+$10.7K	0.01%	266

Other funds holding SNY

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Exane Derivatives's SNY Position: Q2 2020 in Review

Exane Derivatives sold out of Sanofi (SNY) in Q2 2020, closing a stake of 7,700 shares — an estimated $337K sold.

Exane Derivatives first reported a position in SNY in Q3 2015 and held it in 7 quarters. The position peaked at $693K in Q2 2017. 582 funds tracked by Wall St. Rank hold SNY as of Q2 2020.

Exane Derivatives reported no remaining Sanofi position as of Q2 2020 after selling out during the quarter.
Exane Derivatives sold 7,700 Sanofi shares in Q2 2020, an estimated $337K.
Exane Derivatives first reported a position in Sanofi in Q3 2015 and held it in 7 quarters.
Exane Derivatives's Sanofi position peaked at $693K in Q2 2017.
582 funds tracked by Wall St. Rank held Sanofi as of Q2 2020.

Based on Exane Derivatives's 13F filing for Q2 2020, filed 10 Jul 2020.